Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1

Prostaglandins and Other Lipid Mediators

Volumn 89, Issue 3-4, 2009, Pages 126-130

  Seki, Hiroyuki ^a,b   Tani, Yukako ^a   Arita, Makoto ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Inflammation; Lipidomics; Omega 3 PUFA; Resolvins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIGEN; CD59 ANTIGEN; CELL ADHESION MOLECULE; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN; LIPID; LYMPHOCYTE ANTIGEN; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID; RESOLVIN E1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BIOSYNTHESIS; DENDRITIC CELL; ENZYME INACTIVATION; HUMAN; HYPOXIA; INFLAMMATION; MACROPHAGE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; RETINOPATHY; REVIEW; THROMBOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; CELL ADHESION MOLECULES; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; EXUDATES AND TRANSUDATES; FATTY ACIDS, OMEGA-3; HUMANS; INFLAMMATION; MONONUCLEAR PHAGOCYTE SYSTEM; PHAGOCYTES;

EID: 69549086392     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2009.03.002     Document Type: Review

References (43)

1. Nathan C. Points of control in inflammation. Nature 420 6917 (2002) 846-852
2. Erlinger T.P., Platz E.A., Rifai N., and Helzlsouer K.J. C-reactive protein and the risk of incident colorectal cancer. JAMA 291 5 (2004) 585-590
3. Sijben J.W., and Calder P.C. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. Proc Nutr Soc 66 2 (2007) 237-259
4. Corey E.J., Shih C., and Cashman J.R. Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci USA 80 12 (1983) 3581-3584
5. Dyerberg J., Bang H.O., Stoffersen E., Moncada S., and Vane J.R. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?. Lancet 2 8081 (1978) 117-119
6. Needleman P., Raz A., Minkes M.S., Ferrendelli J.A., and Sprecher H. Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci USA 76 2 (1979) 944-948
7. Prescott S.M. The effect of eicosapentaenoic acid on leukotriene B production by human neutrophils. J Biol Chem 259 12 (1984) 7615-7621
8. Lee T.H., Mencia-Huerta J.M., Shih C., Corey E.J., Lewis R.A., and Austen K.F. Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. J Clin Invest 74 6 (1984) 1922-1933
9. Serhan C.N., Clish C.B., Brannon J., Colgan S.P., Chiang N., and Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192 8 (2000) 1197-1204
10. Serhan C.N., Hong S., Gronert K., et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196 8 (2002) 1025-1037
11. Hong S., Gronert K., Devchand P.R., Moussignac R.L., and Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 278 17 (2003) 14677-14687
12. Kang J.X., Wang J., Wu L., and Kang Z.B. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature 427 6974 (2004) 504
13. Hudert C.A., Weylandt K.H., Lu Y., et al. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 103 30 (2006) 11276-11281
14. Jia Q., Lupton J.R., Smith R., et al. Reduced colitis-associated colon cancer in Fat-1 (n-3 fatty acid desaturase) transgenic mice. Cancer Res 68 10 (2008) 3985-3991
15. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 9177 (1999) 447-455
16. Arita M., Bianchini F., Aliberti J., et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201 5 (2005) 713-722
17. Akarasereenont P., Techatrisak K., Chotewuttakorn S., and Thaworn A. The induction of cyclooxygenase-2 in IL-1beta-treated endothelial cells is inhibited by prostaglandin E2 through cAMP. Mediators Inflamm 8 6 (1999) 287-294
18. Tjonahen E., Oh S.F., Siegelman J., et al. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol 13 11 (2006) 1193-1202
19. Arita M., Clish C.B., and Serhan C.N. The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids. Biochem Biophys Res Commun 338 1 (2005) 149-157
20. Haas-Stapleton E.J., Lu Y., Hong S., et al. Candida albicans modulates host defense by biosynthesizing the pro-resolving mediator Resolvin E1. PLoS ONE 2 12 (2007) e1316
21. Hong S., Porter T.F., Lu Y., Oh S.F., Pillai P.S., and Serhan C.N. Resolvin E1 metabolome in local inactivation during inflammation-resolution. J Immunol 180 5 (2008) 3512-3519
22. Chin A.C., and Parkos C.A. Pathobiology of neutrophil transepithelial migration: implications in mediating epithelial injury. Annu Rev Pathol 2 (2007) 111-143
23. Schwab J.M., Chiang N., Arita M., and Serhan C.N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447 7146 (2007) 869-874
24. Arita M., Yoshida M., Hong S., et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA 102 21 (2005) 7671-7676
25. Campbell E.L., Louis N.A., Tomassetti S.E., et al. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J 21 12 (2007) 3162-3170
26. Arita M., Ohira T., Sun Y.P., Elangovan S., Chiang N., and Serhan C.N. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 178 6 (2007) 3912-3917
27. Haworth O., Cernadas M., Yang R., Serhan C.N., and Levy B.D. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A(4) to promote the resolution of allergic airway inflammation. Nat Immunol (2008)
28. Vassiliou E.K., Kesler O.M., Tadros J.H., and Ganea D. Bone marrow-derived dendritic cells generated in the presence of resolvin E1 induce apoptosis of activated CD4+ T cells. J Immunol 181 7 (2008) 4534-4544
29. Dona M., Fredman G., Schwab J.M., et al. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 112 3 (2008) 848-855
30. Dyerberg J., and Bang H.O. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 2 8140 (1979) 433-435
31. Hasturk H., Kantarci A., Ohira T., et al. RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. FASEB J 20 2 (2006) 401-403
32. Hasturk H., Kantarci A., Goguet-Surmenian E., et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol 179 10 (2007) 7021-7029
33. Blumberg R.S., and Strober W. Prospects for research in inflammatory bowel disease. JAMA 285 5 (2001) 643-647
34. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 347 6 (2002) 417-429
35. Aoki H., Hisada T., Ishizuka T., et al. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem Biophys Res Commun 367 2 (2008) 509-515
36. Holgate S.T. The epidemic of allergy and asthma. Nature 402 6760 Suppl. (1999) B2-4
37. Peters-Golden M., and Henderson Jr. W.R. Leukotrienes. N Engl J Med 357 18 (2007) 1841-1854
38. De Rose V., Cappello P., Sorbello V., et al. IFN-gamma inhibits the proliferation of allergen-activated T lymphocytes from atopic, asthmatic patients by inducing Fas/FasL-mediated apoptosis. J Leukoc Biol 76 2 (2004) 423-432
39. Levy B.D., Fokin V.V., Clark J.M., Wakelam M.J., Petasis N.A., and Serhan C.N. Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a 'stop' signaling switch for aspirin-triggered lipoxin A4. FASEB J 13 8 (1999) 903-911
40. Levy B.D., De Sanctis G.T., Devchand P.R., et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med 8 9 (2002) 1018-1023
41. Connor K.M., SanGiovanni J.P., Lofqvist C., et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 13 7 (2007) 868-873
42. Duffield J.S., Hong S., Vaidya V.S., et al. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol 177 9 (2006) 5902-5911
43. Sun Y.P., Oh S.F., Uddin J., et al. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem 282 13 (2007) 9323-9334